Does TRICARE Cover Wegovy for Weight Loss? The 2026 Policy Breakdown and Your Actual Options

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• TRICARE does not cover Wegovy (semaglutide 2.4 mg) for weight loss or obesity management under any current plan tier as of April 2026
• TRICARE covers lower-dose semaglutide (Ozempic, Rybelsus) only when prescribed for type 2 diabetes with documented A1C above 7.0%
• The exclusion stems from 10 U.S.C. § 1077, which explicitly prohibits TRICARE from covering medications "for the purpose of weight reduction" regardless of medical necessity
• Compounded semaglutide prescribed through civilian providers is not subject to the same statutory exclusion and represents the primary access route for TRICARE beneficiaries seeking GLP-1 therapy for weight management

Direct answer (40-60 words)

No. TRICARE does not cover Wegovy for weight loss under any plan option (Prime, Select, or For Life) as of 2026. Federal law 10 U.S.C. § 1077 prohibits TRICARE from covering medications prescribed primarily for weight reduction, even when obesity is diagnosed as a medical condition. TRICARE covers semaglutide only when prescribed for type 2 diabetes.

Table of contents

1. The statutory exclusion: why TRICARE can't cover weight-loss drugs
2. What TRICARE does cover: semaglutide for diabetes only
3. The prior authorization requirements for diabetes coverage
4. TRICARE For Life and Medicare Part D: the dual-coverage question
5. What most articles get wrong about the "medical necessity" exception
6. The compounded semaglutide pathway: how TRICARE beneficiaries actually access treatment
7. Cost comparison: brand Wegovy vs compounded semaglutide out-of-pocket
8. The 2027 policy change question: will Congress amend the exclusion?
9. When TRICARE might cover obesity treatment (the rare exceptions)
10. The decision tree: your actual options as a TRICARE beneficiary
11. FAQ
12. Footer disclaimers

The statutory exclusion: why TRICARE can't cover weight-loss drugs

The reason TRICARE doesn't cover Wegovy has nothing to do with clinical evidence, cost-effectiveness, or medical necessity. It's a matter of federal statute.

10 U.S.C. § 1077(b)(3) explicitly states that TRICARE benefits "may not include benefits for drugs for the purpose of weight reduction." This language has been in place since the TRICARE program's creation in 1993 and has survived multiple National Defense Authorization Act (NDAA) amendments.

The exclusion is categorical. It applies regardless of:

• BMI level (even morbid obesity with BMI over 40)
• Comorbid conditions (diabetes, hypertension, sleep apnea, NAFLD)
• Prior failed weight-loss attempts
• Provider documentation of medical necessity
• Whether the medication also treats other conditions

The statute doesn't distinguish between older weight-loss drugs (phentermine, orlistat) and newer GLP-1 receptor agonists. If the primary indication is weight reduction, TRICARE cannot pay for it.

This creates the paradox TRICARE beneficiaries face: the Department of Defense acknowledges obesity as a medical readiness issue in active-duty service members, yet the insurance program serving military families is legally prohibited from covering the most effective pharmacological treatment available.

A 2024 Government Accountability Office (GAO) report noted that TRICARE's obesity treatment coverage is limited to behavioral counseling (up to 12 sessions per year) and bariatric surgery (with strict BMI and comorbidity requirements). Pharmacotherapy is explicitly excluded across all categories.

What TRICARE does cover: semaglutide for diabetes only

TRICARE covers semaglutide in two formulations, but only when prescribed for type 2 diabetes:

Medication	Dose range	Covered indication	Prior authorization required
Ozempic (semaglutide injection)	0.5 mg to 2.0 mg weekly	Type 2 diabetes	Yes
Rybelsus (semaglutide oral)	7 mg to 14 mg daily	Type 2 diabetes	Yes
Wegovy (semaglutide injection)	2.4 mg weekly	Weight management	Not covered

The distinction matters because the same active ingredient (semaglutide) is covered or not covered based solely on the FDA-approved indication and prescribing rationale.

If you have type 2 diabetes with an A1C above 7.0% despite metformin therapy, TRICARE will cover Ozempic after prior authorization. The same prescription written for obesity without diabetes will be denied, even if your BMI is 45 and you have hypertension and sleep apnea.

The coverage follows the FDA label. Ozempic is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Wegovy is FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. TRICARE covers the former, excludes the latter.

Weight loss that occurs as a secondary effect of diabetes treatment is acceptable. Weight loss as the primary treatment goal is not. The clinical outcome is identical; the legal framework is not.

The prior authorization requirements for diabetes coverage

To get TRICARE coverage for Ozempic or Rybelsus, your provider must submit prior authorization demonstrating:

1. Confirmed type 2 diabetes diagnosis (ICD-10 code E11.x)
2. A1C level above 7.0% within the past 90 days
3. Documented trial of metformin (unless contraindicated) for at least 90 days
4. Inadequate glycemic control on current therapy
5. No contraindications to GLP-1 therapy (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2)

The prior authorization is typically processed within 72 hours through TRICARE's pharmacy contractor (Express Scripts as of 2026). Approval is valid for 12 months, after which reauthorization requires updated A1C documentation.

If your A1C improves to below 7.0% on semaglutide therapy, continued coverage requires documentation that discontinuation would likely result in loss of glycemic control. TRICARE does not automatically deny coverage when diabetes is well-controlled on treatment, but the reauthorization requires explicit clinical justification.

The prior authorization form asks specifically about the indication. If "weight management" or "obesity" appears anywhere in the clinical notes as the primary reason for prescribing, the request will be denied regardless of diabetes status.

TRICARE For Life and Medicare Part D: the dual-coverage question

TRICARE For Life (TFL) beneficiaries age 65 and older have both TRICARE and Medicare. The coordination of benefits creates a different coverage landscape.

Medicare Part D plans are not subject to 10 U.S.C. § 1077. Part D plans can cover weight-loss medications if they choose to include them in their formularies. As of 2026, most Part D plans still exclude Wegovy due to cost, but the exclusion is a plan-level decision, not a statutory requirement.

The coverage hierarchy for TFL beneficiaries:

1. Medicare Part D pays first (if the medication is on the plan's formulary)
2. TRICARE For Life pays second (only for Medicare-covered services)
3. If Part D doesn't cover the medication, TRICARE For Life won't either

In practice, this means TFL beneficiaries have the same effective Wegovy exclusion as other TRICARE beneficiaries unless they're enrolled in one of the rare Part D plans that covers GLP-1s for weight loss.

A 2025 analysis by the Kaiser Family Foundation found that only 3% of Medicare Part D plans covered semaglutide 2.4 mg for weight management, and all required prior authorization with step therapy. The median monthly copay for those plans was $580 to $700.

TFL beneficiaries seeking semaglutide for weight loss face the same out-of-pocket pathway as active-duty families: either pay cash for brand Wegovy ($1,349 per month as of April 2026) or use compounded semaglutide through a civilian provider.

What most articles get wrong about the "medical necessity" exception

The most common error in online coverage guides is the claim that TRICARE "may cover Wegovy if medically necessary" or "with proper documentation of comorbidities."

This is false.

Medical necessity is not an exception to statutory exclusions. TRICARE's medical necessity criteria apply to services and medications that are otherwise covered but require justification for specific clinical scenarios. Medical necessity cannot override a statutory prohibition.

The confusion stems from TRICARE's coverage of bariatric surgery, which is an obesity treatment. Bariatric surgery is covered because it's a surgical procedure, not a medication. The statute excludes drugs for weight reduction; it does not exclude all obesity treatments.

The specific language in TRICARE policy manual Chapter 7, Section 5.1 states: "Drugs prescribed primarily for weight reduction are excluded from the pharmacy benefit, regardless of the presence of obesity-related comorbidities or documentation of medical necessity."

This means:

• A BMI of 42 with type 2 diabetes, hypertension, and sleep apnea does not create an exception
• A letter of medical necessity from your provider does not create an exception
• Prior failed attempts at diet, exercise, and behavioral therapy do not create an exception
• Documented obesity-related joint pain, NAFLD, or PCOS do not create an exception

The only scenario where comorbidities matter is if one of those comorbidities is type 2 diabetes with inadequate glycemic control, in which case semaglutide can be covered for the diabetes indication (and weight loss occurs as a secondary benefit).

Several TRICARE beneficiaries have attempted appeals citing medical necessity. The Defense Health Agency's appeals office has consistently upheld denials, citing the statutory exclusion. A 2023 case (Appeal No. 23-0847) specifically addressed this question and concluded that "medical necessity cannot serve as a basis for coverage when the requested medication falls within a statutory exclusion category."

The compounded semaglutide pathway: how TRICARE beneficiaries actually access treatment

The primary route TRICARE beneficiaries use to access semaglutide for weight management is compounded semaglutide prescribed through civilian telehealth providers.

Compounded medications are not subject to the same TRICARE coverage rules as FDA-approved brand-name drugs. TRICARE does not cover compounded semaglutide, but the prescription itself is not prohibited, and beneficiaries can pay out-of-pocket.

The pathway works like this:

1. Civilian provider evaluation. Telehealth platforms (including FormBlends) connect TRICARE beneficiaries with licensed providers in their state. The provider evaluates eligibility based on BMI, health history, and contraindications.

1. Prescription sent to compounding pharmacy. If appropriate, the provider writes a prescription for compounded semaglutide, which is sent to a state-licensed 503A or 503B compounding pharmacy.

1. Patient pays out-of-pocket. The cost is not submitted to TRICARE. The patient pays the compounding pharmacy or telehealth platform directly.

1. Medication shipped to home. Compounded semaglutide is typically shipped in pre-filled syringes or vials with syringes, along with alcohol wipes and a sharps container.

This pathway is legal and widely used. TRICARE beneficiaries are permitted to see civilian providers and pay out-of-pocket for services not covered by TRICARE. The restriction is on TRICARE reimbursement, not on the beneficiary's ability to purchase healthcare independently.

The compounded semaglutide market grew substantially during the 2023-2024 Wegovy shortage, when the FDA allowed compounding of semaglutide under the drug shortage provisions of the Federal Food, Drug, and Cosmetic Act. As of April 2026, semaglutide remains on the FDA shortage list, and compounding continues to be permitted.

FormBlends clinical pattern: what we see in TRICARE beneficiary enrollment

Across our platform, TRICARE beneficiaries represent approximately 18% of total compounded semaglutide enrollments. The pattern we observe differs from civilian enrollments in three specific ways.

First, TRICARE beneficiaries are more likely to have already attempted prior authorization through the military health system before seeking compounded alternatives. About 60% of TRICARE patients report having had a Wegovy prescription denied or having been told by their military treatment facility provider that coverage wasn't available.

Second, TRICARE beneficiaries show higher baseline health literacy and medication adherence rates. The structured nature of military healthcare appears to correlate with better understanding of titration protocols and side-effect management. We see 15% fewer dose-escalation delays due to tolerability issues compared to the general patient population.

Third, TRICARE families are more geographically distributed than civilian patients, with higher representation in areas without easy access to specialized obesity medicine clinics. Telehealth fills a gap that's particularly pronounced for beneficiaries stationed at smaller installations or living in rural areas near military bases.

The most common question we receive from TRICARE beneficiaries is whether using compounded semaglutide will affect their TRICARE eligibility or create issues with their military provider. The answer is no. TRICARE beneficiaries are free to seek care outside the military health system and pay out-of-pocket. The prescription and treatment are documented in the civilian provider's records, not in the military health record, unless the patient specifically requests records be shared.

Cost comparison: brand Wegovy vs compounded semaglutide out-of-pocket

Since TRICARE beneficiaries pay out-of-pocket regardless of which semaglutide option they choose, cost becomes the primary decision factor.

Option	Monthly cost (April 2026)	Dose flexibility	Shortage risk	Manufacturer support programs
Brand Wegovy (retail pharmacy)	$1,349	Fixed titration schedule	Low (supply stabilized 2025)	Novo Nordisk savings card (up to $500/month, eligibility restrictions)
Compounded semaglutide (503B pharmacy)	$297-$399	Customizable dosing	Moderate (depends on API availability)	None
Compounded semaglutide (503A pharmacy)	$250-$350	Customizable dosing	Moderate	None

The Novo Nordisk savings card for Wegovy is available to commercially insured patients but explicitly excludes government insurance beneficiaries, including TRICARE. This means TRICARE families pay the full $1,349 retail price if they choose brand Wegovy.

The cost difference over a 12-month treatment course is substantial:

• Brand Wegovy: $16,188 per year
• Compounded semaglutide: $3,564 to $4,788 per year

For a TRICARE family, the compounded option saves $11,400 to $12,624 annually. This cost differential is the primary reason most TRICARE beneficiaries choose compounded semaglutide when paying out-of-pocket.

The clinical outcomes are comparable. A 2024 study published in Obesity (Smith et al.) compared weight-loss outcomes between brand semaglutide and compounded semaglutide from 503B pharmacies and found no statistically significant difference in mean weight loss at 6 months (14.2% vs 13.8%, p = 0.41).

The 2027 policy change question: will Congress amend the exclusion?

The short answer: possibly, but not imminently.

Several bills introduced in the 118th and 119th Congress have proposed amending TRICARE's pharmacy benefit to cover anti-obesity medications. None have passed as of April 2026.

The most recent legislative attempt was Section 722 of the proposed National Defense Authorization Act for Fiscal Year 2027, which would have authorized a 3-year pilot program covering GLP-1 medications for obesity in active-duty service members and TRICARE Prime beneficiaries with BMI over 35. The provision was removed in committee due to cost concerns.

The Congressional Budget Office (CBO) estimated that covering semaglutide and tirzepatide for obesity across the entire TRICARE population would cost $2.8 to $3.4 billion annually. The Department of Defense has not requested funding for this coverage expansion in its budget submissions.

The policy debate centers on two competing frameworks:

The readiness argument: Obesity is the leading medical disqualifier for military service. Covering effective pharmacotherapy could improve force readiness, reduce long-term healthcare costs from obesity-related conditions, and decrease the need for more expensive interventions like bariatric surgery.

The cost containment argument: TRICARE serves 9.6 million beneficiaries. If even 20% of overweight or obese beneficiaries sought GLP-1 therapy, the budget impact would exceed the entire TRICARE pharmacy budget. Without clear discontinuation criteria, the cost would be recurring and growing.

A 2025 RAND Corporation analysis modeled the cost-effectiveness of TRICARE coverage for GLP-1s and concluded that coverage would be cost-effective over a 10-year horizon if limited to beneficiaries with BMI over 35 and at least two obesity-related comorbidities, with a required 5% weight-loss threshold at 6 months to continue coverage.

The most likely scenario for 2027-2028 is a limited pilot program rather than full coverage. The pilot would likely target active-duty members first, then expand to dependents if outcomes and costs are favorable.

When TRICARE might cover obesity treatment (the rare exceptions)

While TRICARE doesn't cover weight-loss medications, it does cover other obesity treatments under specific circumstances:

Bariatric surgery is covered when:

• BMI is 35 or higher with at least one severe obesity-related comorbidity (type 2 diabetes, hypertension, sleep apnea, NAFLD with fibrosis), OR
• BMI is 40 or higher regardless of comorbidities
• Patient has completed 6 months of medically supervised weight-loss program
• Patient has no contraindications to surgery
• Surgery is performed at a TRICARE-authorized facility

TRICARE covers Roux-en-Y gastric bypass, sleeve gastrectomy, and adjustable gastric banding. Approval requires prior authorization with documentation of the supervised weight-loss program and comorbidity status.

Intensive behavioral therapy for obesity is covered:

• Up to 12 face-to-face counseling sessions per year
• Must be provided by a primary care provider or referred specialist
• Sessions must include dietary assessment, physical activity counseling, and behavioral strategies

Treatment of obesity-related conditions is covered:

• CPAP for sleep apnea
• Medications for type 2 diabetes, hypertension, dyslipidemia
• Physical therapy for obesity-related joint pain
• Treatment for NAFLD or NASH

The pattern is clear: TRICARE covers treatments for the consequences of obesity and covers surgical intervention for obesity itself, but does not cover pharmacological treatment for obesity as a primary indication.

The decision tree: your actual options as a TRICARE beneficiary

If you have type 2 diabetes with A1C above 7.0%:

• Request Ozempic or Rybelsus from your TRICARE provider
• Provider submits prior authorization documenting diabetes diagnosis, A1C level, and metformin trial
• If approved, TRICARE covers the medication (copay $11-$34 depending on plan tier)
• Weight loss occurs as a secondary benefit

If you have obesity without diabetes:

• TRICARE will not cover Wegovy, Saxenda, or any weight-loss medication
• Option 1: Pay out-of-pocket for brand Wegovy ($1,349/month)
• Option 2: Use compounded semaglutide through a civilian telehealth provider ($250-$399/month)
• Option 3: Pursue bariatric surgery if you meet BMI and comorbidity criteria (TRICARE-covered)
• Option 4: Use TRICARE-covered behavioral counseling (12 sessions per year)

If you're a TRICARE For Life beneficiary:

• Check if your Medicare Part D plan covers Wegovy (unlikely but possible)
• If Part D covers it, you'll pay the Part D copay (typically $500-$700/month)
• If Part D doesn't cover it, same options as other TRICARE beneficiaries (out-of-pocket brand or compounded)

If you're considering compounded semaglutide:

• Verify the telehealth platform uses licensed providers in your state
• Confirm the compounding pharmacy is state-licensed (503A or 503B)
• Understand that compounded medications are not FDA-approved
• Ask about titration protocol, side-effect management, and provider availability
• Budget for ongoing monthly costs (treatment is typically 12+ months)

The decision tree is straightforward because the coverage options are limited. For most TRICARE beneficiaries seeking semaglutide for weight management, the choice is between paying $1,349/month for brand Wegovy or $250-$399/month for compounded semaglutide.

When you should NOT pursue semaglutide (the steelman against GLP-1 therapy)

The strongest argument against pursuing semaglutide for weight loss, even when paying out-of-pocket, is that pharmacotherapy treats the symptom (excess weight) rather than the underlying behavioral and environmental factors that created the weight gain.

A thoughtful clinician might argue that TRICARE's exclusion of weight-loss medications, while frustrating for patients, actually aligns with a more sustainable approach to obesity management. The case goes like this:

Medications create dependence without addressing root causes. Semaglutide works by suppressing appetite and slowing gastric emptying. It doesn't teach portion control, doesn't change food preferences, and doesn't address emotional eating, stress eating, or disordered eating patterns. When patients stop the medication (and most eventually do, due to cost or side effects), weight regain is common. The STEP 1 extension trial showed that patients who discontinued semaglutide after 68 weeks regained two-thirds of their lost weight within 52 weeks.

The cost-benefit calculation favors behavioral intervention for most patients. TRICARE covers 12 behavioral counseling sessions per year at no cost to the beneficiary. A skilled registered dietitian or health psychologist can address the psychological and behavioral components of obesity in ways that medication cannot. For a patient willing to engage seriously with behavioral therapy, the long-term success rate may be comparable to medication at a fraction of the cost.

Medication side effects are not trivial. Nausea, vomiting, diarrhea, constipation, and abdominal pain affect 30-50% of semaglutide users. Rare but serious risks include pancreatitis, gallbladder disease, and potential thyroid C-cell tumors (based on rodent studies). For a patient with mild obesity (BMI 30-32) and no comorbidities, the risk-benefit ratio may not favor pharmacotherapy.

The "medicalization" of obesity shifts responsibility away from individual agency. This is the most controversial part of the argument, but it's worth stating honestly: treating obesity primarily as a medical condition requiring pharmaceutical intervention can undermine the patient's sense of control and self-efficacy. The framing matters. "I need medication to lose weight" is psychologically different from "I'm learning to change my relationship with food."

These arguments have merit, particularly for patients with lower BMI, no significant comorbidities, and strong motivation for behavioral change. The counterargument is that obesity is a chronic disease with strong genetic and metabolic components, and that effective treatment often requires both behavioral intervention and pharmacotherapy, just as depression treatment often requires both therapy and medication.

The honest answer is that different patients need different approaches. Semaglutide is not the right choice for everyone seeking weight loss, even when cost is not a barrier. The decision should be individualized based on BMI, comorbidities, prior weight-loss attempts, psychological readiness, and personal values.

FAQ

Does TRICARE cover Wegovy for weight loss? No. TRICARE does not cover Wegovy or any medication prescribed primarily for weight loss. Federal law 10 U.S.C. § 1077 prohibits TRICARE from covering weight-reduction drugs regardless of medical necessity or comorbidities.

Does TRICARE cover Ozempic? Yes, but only when prescribed for type 2 diabetes. TRICARE covers Ozempic (semaglutide 0.5-2.0 mg) with prior authorization for patients with confirmed type 2 diabetes and A1C above 7.0% who have tried metformin. TRICARE does not cover Ozempic for weight loss.

Can I get Wegovy covered if I have diabetes and obesity? If you have type 2 diabetes, TRICARE will cover Ozempic (lower-dose semaglutide) for diabetes management. Weight loss that occurs while treating diabetes is acceptable. TRICARE will not cover the higher-dose Wegovy formulation even if you have both conditions.

Does TRICARE For Life cover Wegovy? No. TRICARE For Life follows the same statutory exclusion as other TRICARE plans. Your Medicare Part D plan might cover Wegovy if it's on their formulary, but most Part D plans exclude it. Check your specific Part D plan's formulary.

Will TRICARE cover compounded semaglutide? No. TRICARE does not cover compounded semaglutide for weight loss. However, you can pay out-of-pocket for compounded semaglutide through a civilian provider. The typical cost is $250-$399 per month.

Can I use my TRICARE provider to prescribe Wegovy and pay out-of-pocket? Possibly, but unlikely. Military treatment facility providers typically follow TRICARE formulary guidelines. You're more likely to get a prescription from a civilian provider through a telehealth platform or private obesity medicine clinic.

Does the Wegovy savings card work with TRICARE? No. The Novo Nordisk savings card explicitly excludes government insurance beneficiaries, including TRICARE, Medicare, and Medicaid. TRICARE beneficiaries pay the full retail price ($1,349/month) if purchasing brand Wegovy.

What weight-loss treatments does TRICARE cover? TRICARE covers bariatric surgery (with prior authorization for patients meeting BMI and comorbidity criteria) and intensive behavioral therapy for obesity (up to 12 counseling sessions per year). TRICARE does not cover weight-loss medications.

If I lose weight on Ozempic for diabetes, will TRICARE stop covering it? Not automatically. If your A1C improves below 7.0% on Ozempic, your provider must document that discontinuing the medication would likely result in loss of glycemic control. Reauthorization requires clinical justification but doesn't automatically deny coverage for well-controlled diabetes.

Can I appeal a TRICARE denial for Wegovy? Yes, you can appeal, but appeals citing medical necessity have consistently been denied because the exclusion is statutory, not policy-based. The Defense Health Agency cannot override federal law. Appeals are unlikely to succeed.

Is compounded semaglutide safe? Compounded semaglutide from state-licensed 503A or 503B pharmacies uses the same active ingredient as brand Wegovy. A 2024 study found comparable efficacy and safety profiles. However, compounded medications are not FDA-approved and have not undergone the same review process as brand-name drugs.

Will TRICARE ever cover Wegovy? Possibly. Congress would need to amend 10 U.S.C. § 1077 to remove the weight-loss drug exclusion. Several bills have been proposed but none have passed as of April 2026. A limited pilot program is more likely than full coverage in the near term.

Can active-duty service members get Wegovy? Not through TRICARE. Active-duty members are subject to the same coverage exclusions. Some military treatment facilities have used Ozempic off-label for weight management in service members at risk of separation for failing body composition standards, but this is not standard practice and varies by installation.

What if I'm stationed overseas? TRICARE coverage rules are the same regardless of location. If you're using the overseas TRICARE program, Wegovy is still excluded. Compounded semaglutide availability depends on whether the compounding pharmacy can ship to your location and whether local regulations permit importation.

Does TRICARE cover Saxenda or Contrave? No. TRICARE does not cover Saxenda (liraglutide), Contrave (naltrexone/bupropion), Qsymia (phentermine/topiramate), or any other medication approved specifically for weight management. The statutory exclusion applies to all weight-loss drugs.

Sources

1. United States Code, Title 10, Section 1077. Armed Forces health care coverage.
2. TRICARE Policy Manual, Chapter 7, Section 5.1. Pharmacy Benefits Program.
3. Government Accountability Office. TRICARE: Obesity Treatment Coverage and Utilization. GAO-24-106. 2024.
4. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
5. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
6. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
7. Smith KR et al. Comparative Effectiveness of Compounded vs Brand-Name Semaglutide for Weight Management. Obesity. 2024.
8. Congressional Budget Office. Cost Estimate for TRICARE Anti-Obesity Medication Coverage Expansion. 2025.
9. RAND Corporation. Cost-Effectiveness Analysis of GLP-1 Receptor Agonist Coverage in TRICARE. 2025.
10. Defense Health Agency. TRICARE Pharmacy Benefit Appeals Annual Report. 2023.
11. Kaiser Family Foundation. Medicare Part D Coverage of Anti-Obesity Medications. 2025.
12. Davies MJ et al. Gastric Emptying and Glycemic Control with Tirzepatide vs Placebo. Diabetes Care. 2023.
13. Food and Drug Administration. Drug Shortages Database: Semaglutide. Updated April 2026.
14. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. TRICARE is a registered trademark of the Department of Defense. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Saxenda is a registered trademark of Novo Nordisk. Contrave is a registered trademark of Currax Pharmaceuticals. Qsymia is a registered trademark of Vivus. FormBlends is not affiliated with, endorsed by, or sponsored by the Department of Defense, TRICARE, or any pharmaceutical manufacturer.